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Neuroendocrine secretory protein 55, NESP55, is an acidic protein belonging to the chromogranin family. The distribution of
NESP55 in human tumours is not known. The aim of the present study was to study the expression of NESP55 in human
gastrointestinal, pancreatic and adrenal tumours. A total of 118 human endocrine and nonendocrine tumours were examined by
immunocytochemistry, and compared to the expression of chromogranin A (CgA) in the same tumours. Pancreatic endocrine
tumours (14 out of 25), pheochromocytomas (19 out of 19), and neuroblastomas (seven out of 14) expressed NESP55, with the
same strong labelling pattern in both benign and malignant tumours. Expression of NESP55 in pancreatic endocrine tumours and
pheochromocytomas was confirmed by Western and Northern blot analysis. Immunocytochemical analysis demonstrated no
labelling in ileal carcinoids (zero out of 15), and adrenocortical adenomas (zero out of 15). The majority of gastrointestinal and
pancreatic carcinomas were negative for NESP55, with focal staining observed in two out of 30 tumours. In contrast, CgA was
present in all neuroendocrine tumours examined (25 out of 25 pancreatic endocrine tumours, 19 out of 19 pheochromocytomas,
14 out of 14 neuroblastomas and 15 out of 15 ileal carcinoids). Thus, the expression of NESP55 in endocrine tumours of the
gastrointestinal tract, pancreas and adrenals differs from that of CgA. Neuroendocrine secretory protein 55 is found in a subset of
neuroendocrine tumours showing differentiation towards adrenal chromaffin cells and pancreatic islets cells.
British Journal of Cancer (2003) 88, 1746–1754. doi:10.1038/sj.bjc.6600924 www.bjcancer.com
& 2003 Cancer Research UK
Keywords: NESP55; chromogranin; endocrine tumours; gastrointestinal tract; pancreas; adrenal gland
                                                 
Neuroendocrine tumours may arise in several organs, and have a
common set of genes and markers, for example, hormones, vesicle
proteins and enzymes. These proteins can be used as markers to
distinguish the neuroendocrine tumours from nonendocrine
tumours. The identification of a neuroendocrine tumour pheno-
type carries important prognostic and therapeutic implications.
Endocrine tumours of the gut and pancreas have much better
prognosis and responsiveness to therapy than their nonendocrine
counterparts. However, endocrine differentiation may indicate a
very aggressive clinical behaviour and poor prognosis in a subset
of tumours, such as the poorly differentiated endocrine carcino-
mas (PDEC). Consequently, there is a need for specific and
sensitive markers of neuroendocrine differentiation in diagnostic
histopathology.
Accurate demonstration of neuroendocrine differentiation in
tumours requires a broad spectrum of diagnostic tools. Immuno-
cytochemical demonstration of secretory granule/vesicle proteins
such as chromogranin A (CgA) and synaptophysin is the
method of choice (Lloyd and Wilson, 1983) in demonstrating
neuroendocrine differentiation. The huge biological diversity of
neuroendocrine tumours necessitates the use of multiple neuro-
endocrine markers in order to detect and characterise all types of
neuroendocrine tumours. Chromogranins constitute a group of
acidic proteins which are widely expressed in neuroendocrine
tissues (Simon and Aunis, 1989; Winkler and Fischer-Colbrie,
1992). They are localised to large dense core vesicles. Members of
the chromogranin family are CgA and CgB, secretogranin II and
III, VGF and neuroendocrine secretory protein 55 (NESP55)
(Laslop et al, 2000). The physiological functions of chromogranins
are still poorly understood. However, CgA has been shown to
regulate secretory granule formation (Kim et al, 2001), and
chromogranins are also known to be cleaved by endopeptidases to
smaller biologically active peptide fragments such as pancreastatin,
vasostatin I and II, and secretoneurin (Laslop et al, 2000).
Neuroendocrine secretory protein 55, the latest discovered
member of the chromogranin family, is an acidic protein with an
Mr 55000. It has been cloned from cultured bovine chromaffin
cells (Ischia et al, 1997), rat pituitary (Weiss et al, 2000) and a
mouse pancreatic islet cell line (Hayward et al, 1998b) as well as
from a human pheochromocytoma (Weiss et al, 2000). The
NESP55-gene is genomically imprinted (Hayward et al, 1998a)
and transcribed exclusively from the maternal allele (Li et al,
2000). Northern blot experiments have revealed a complex pattern Revised 17 January 2003; accepted 25 February 2003
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et al, 2000). Neuroendocrine secretory protein 55 is highly
conserved among mammalian species. It is comprised of 245
amino acids with a predicted molecular mass of 28kDa (Ischia
et al, 1997), and is post-translationally modified by the addition of
keratan sulphate glycosamine glycan chains (Weiss et al, 2000).
The primary amino-acid structure of NESP55 contains five pairs of
dibasic amino-acid residues, at which NESP55 can be cleaved by
endopeptidases. Proteolytic processing of NESP55 is tissue
dependent and varies greatly (Weiss et al, 2000). In the bovine
adrenal medulla, NESP55 is cleaved efficiently to intermediate-
sized and smaller molecules such as the C-terminal octapeptide
(GAIPIRRH) (Ischia et al, 1997). In contrast, very little processing
has been observed in the rat central nervous system (Weiss et al,
2000).
In bovine tissues, NESP55 was found at highest concentrations
in the adrenal medulla; lower concentrations were found in the
anterior pituitary, posterior pituitary and brain, pancreas, serum
and urine. Neuroendocrine secretory protein 55 was not detected
by RIA in the thyroid gland, lung, liver, spleen and testis. Very low
concentrations of NESP55 were found in the intestines (Lovisetti-
Scamihorn et al, 1999). Thus, the distribution of NESP55 resembles
that of chromogranin A, but it may be less widely distributed.
Neuroendocrine secretory protein 55 is expressed in the brain in
phylogenetically old areas such as the brain stem and the
hypothalamus (Bauer et al, 1999), which are involved in the
regulation of basic autonomic and endocrine function. The aim of
the present study was to analyse the expression of NESP55 protein
in neuroendocrine tumours of the gastrointerstinal tract, pancreas
and adrenals, and to evaluate the relation between NESP55
expression, tumour type and biological behaviour.
MATERIALS AND METHODS
Tumour material
A total of 118 human tumours from the files of the Department of
Pathology, Sahlgrenska University Hospital, were analysed by
immunohistochemistry. The following tumours were investigated:
ileal endocrine tumours (ileal carcinoids) (n¼15), pancreatic
endocrine tumours (n¼25), neuroblastomas (n¼14), pheochromo-
cytomas (n¼19), adrenocortical adenomas (n¼15) as well as
nonendocrine tumours (adenocarcinomas) of the gastrointestinal
tract and pancreas (n¼30). Fresh tumour material was obtained
from 35 patients undergoing surgery and was subjected to Western
blot analysis: ileal carcinoids (n¼9), pancreatic endocrine
tumours (n¼9), pheochromocytomas (n¼9) and nonendocrine
gastrointestinal tumours (adenocarcinomas) (n¼8). Northern blot
was performed on pheochromocytomas and ileal carcinoids.
Immunocytochemistry
Tumour tissues were fixed in buffered formalin, dehydrated and
embedded in paraffin wax. Sections (3–4mm) were placed on
positively charged glass slides, deparaffinised and rehydrated.
After microwave treatment with EDTA–NaOH, pH 8, twice for
5min (NESP55 and tyrosine hydroxylase (TH)) or citrate buffer,
pH 6 (CgA and insulin), sections were rinsed, blocked and
incubated with primary antibodies overnight. Details of primary
antibodies are given in Table 1. Neuroendocrine secretory protein
55 antisera were raised in rabbits immunised with a synthetic
C-terminal fragment of bovine NESP55 (GAIPIRRH) coupled to
keyhole limpet haemocyanin. The antibody reacts with bovine
tissue which contains the NESP55 protein (Ischia et al, 1997).
Bound antibodies were visualised using an indirect immunoper-
oxidase technique (EnVisionþt, cat. no. K4002/rabbit, K4000/
mouse; DAKO, Denmark). Diaminobenzidine (DAB) was used as
chromogen. After counterstaining with Mayer’s haematoxylin,
sections were dehydrated and mounted. Slides were coded and
evaluated by three observers. Immunolabelling was graded as
follows: 0¼o1% positive tumour cells, 1þ¼1–24% positive
tumour cells, 2þ¼25–75% positive tumour cells and 3þ¼
475% positive tumour cells. In control experiments, the NESP55
antiserum was adsorbed with a synthetic peptide fragment of
human NESP55 (GPIPIRRH), at 0.01–1mM overnight prior to
immunocytochemical staining.
Western blot
Fresh tumour tissues were snap frozen in liquid nitrogen and
stored at  1401C until preparation. Frozen tissue (approximately
20mg) was homogenised in 10mM potassium phosphate buffer,
pH 6.8, containing 1mM EDTA, 10mM 3-(3-cholamidopropyl)
dimethylammonio 1-propane sulphate (CHAPS), 1mgml
 1 apro-
tinin, and 10mgml
 1 each of leupeptin and pepstatin and
1mgml
 1 of 4-(2-aminoethyl)-benzenesulphonyl fluoride (Pefa-
block
s SC, Boehringer Mannheim, Mannheim, Germany). Homo-
genates were sonicated twice for 15s, followed by centrifugation
for 10min at 10000g. The clear supernatant was withdrawn,
assayed for protein content according to Bradford and stored at
 801C. Aliquots of proteins (20mg) were diluted in NuPaget
LDS sample buffer (cat. no. NP 0007, In Vitrogen, Carlsbad, CA,
USA). Reducing agent was added, followed by denaturation at 701C
for 10min and electrophoresis on precast polyacrylamide gels
(10% NuPaget Bis-Tris-gels, cat. no. NP 0301 In Vitrogen) using
NuPaget MOPS SDS (cat. no. NP 0001, In Vitrogen) as running
buffer. The proteins were transferred to polyvinyl difluoride
(PVDF) membranes (cat. no. 43660, BDH 4 Q Poole, UK) using the
NOVEX blotting system. Membranes were incubated with rabbit
polyclonal anti-NESP55 antibody (Ischia et al, 1997) at 41C
overnight followed by alkaline phosphatase-conjugated goat anti-
rabbit antibody (cat. no. AC31RL, Tropix, Applied Biosystems
MSC 050, Bedford, MA, USA) and CDP-Star (Tropix, Applied
Biosystems) as substrate. Membranes were exposed to ECL film
(RPN 3103K, Amersham Pharmacia Biotech, Buckinghamshire,
UK) at room temperature for 10–300s. Molecular weight markers
(SeeBluet, LC 5625, In Vitrogen) were used to calculate the
apparent size of immunoreactive proteins. In control experiments,
the NESP55 antiserum was adsorbed with a synthetic peptide
fragment of human NESP55 (GPIPIRRH) at 1mM overnight prior to
incubation with membranes.
Table 1 Antibodies used for immunocytochemistry
Antibody Species Dilution Clone Cat. no. Source Ref.
Anti-NESP55 Rabbit 1:100 — — Reiner Fischer-Colbrie, Innsbruck, Austria Ischia et al (1997)
Anti-CgA Mouse 1:1000 LK2H10 1199021 Boehringer Mannheim, Mannheim, Germany Lloyd and Wilson (1983)
Anti-TH Mouse 1:150 2/40/15 1017381 Boehringer Mannheim, Mannheim, Germany Rohrer et al (1998)
Anti-insulin Guinea pig 1:100 — A0564 DAKO A/S, Copenhagen —
NESP55¼neuroendocrine secretory protein, CgA¼chromogranin A, TH¼tyrosine hydroxylase.
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Total RNA was extracted from tumour tissue by the acid
guanidinium thiocyanate method. Total RNA was size fractionated
on 1% agarose gels with 2.2 M formaldehyde and transferred to
nylon membranes (Boehringer Mannheim, Darmstadt, Germany).
RNA was crosslinked to membranes by UV-light (Stratagene, CA,
USA). Membranes were prehybridised in SSC buffer containing
50% formamide for 1–2h at 601C and hybridised overnight at
601C with a NESP55 antisense probe labelled with [a-
32 P]-UTP.
After stringent washing, membranes were exposed to imaging
plates (K screen) at room temperature and read in a Molecular
Imager
R FX (Bio-Rad, CA, USA). The NESP55 probe was a 266-bp
fragment of human NESP55 (nucleotides 1090–1356, accession
number AJ009849) generated by PCR-amplification of a c-DNA
fragment from a human pheochromocytoma subcloned into
pPCR-Scriptt Amp SK (þ) cloning vector (Stratagene). The
identity of the cloned NESP55 cDNA fragment was confirmed by
sequence analysis. Radiolabelled antisense probe was generated
using T3 RNA polymerase.
RESULTS
Immunocytochemical localisation of NESP55 and CgA in
normal gastrointestinal tract, pancreas and adrenal gland
Gastrointestinal tract NESP55 labelling was observed over a few
cells in the mucosa of the gastric antrum. Labelled cells were
located in the lower half of the antral glands. No NESP55 labelling
was observed in the mucosa of the small intestine and colon. In the
submucous and myenteric plexa, a few NESP55-labelled ganglion
cells were observed. Numerous CgA-positive endocrine cells were
observed in the mucosa at all levels of the gastrointestinal tract. A
few CgA-positive nerve fibres and ganglion cells were observed in
the myenteric and submucous nerve plexa at all levels of the
gastrointestinal tract.
Pancreas Neuroendocrine secretory protein 55 labelling was
observed in pancreatic islets, while exocrine parenchyma was
devoid of labelling. The majority of NESP55 labelling was located
in beta-cells, as evident from consecutive staining for NESP55,
CgA NESP55 Insulin
Figure 1 Immunocytochemical demonstration of CgA, NESP55 and insulin in a pancreatic islet. Consecutive sections were stained with an indirect
immunoperoxidase technique (EnVisionþt). The majority of pancreatic b-cells (insulin positive) are also positive for CgA and NESP55.
CgA NESP55 TH
Figure 2 Immunocytochemical demonstration of CgA, NESP55 and TH in normal adrenal medulla. Consecutive sections were stained with an indirect
immunoperoxidase technique (EnVisionþt). The majority of chromaffin cells are positive for CgA, NESP55 and TH.
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cytoplasmic, with an accumulation of labelling in the perinuclear
region. All labelling was abolished after adsorption of NESP55
antiserum with 1mM synthetic human NESP55 peptide. Chromo-
granin A labelling was also located to pancreatic islets, with no
labelling over exocrine parenchyma. The CgA labelling in
pancreatic islets was cytoplasmic with a characteristic granular
pattern (Figure 1).
Adrenal gland The chromaffin cells in the adrenal medulla were
labelled by the NESP55 antibody, while none of the parenchymal
cells of the adrenal cortex were labelled. The NESP55 labelling
pattern in chromaffin cells was cytoplasmic, with an accumulation
of labelling in the perinuclear region. All labelling was abolished
after adsorption of NESP55 antiserum with 1mM synthetic human
NESP55 peptide. Chromogranin A was also located to the adrenal
medulla and showed a characteristic granular labelling pattern in
the chromaffin cells (Figure 2).
Immunocytochemical localisation of NESP55 and CgA
in endocrine and nonendocrine tumours of the
gastrointestinal tract, pancreas and adrenal
Ileal endocrine tumours A total of 15 tumours were analysed.
Tumours were classified according to WHO 2000 (Socia et al,
2000) as being well-differentiated endocrine carcinomas (malig-
nant carcinoids). All tumours had metastatic spread to regional
lymph nodes and/or liver. All patients had a typical midgut
carcinoid syndrome with overproduction of serotonin. Immuno-
cytochemical analysis did not demonstrate any NESP55 labelling in
the ileal carcinoids (0 out of 15), while all tumours (15 out of 15)
were strongly positive for CgA (Table 2).
Pancreatic endocrine tumours A total of 25 tumours were
analysed and classified according to WHO 2000. The criteria for
malignancy was invasion of contiguous structures or documented
metastases. The tumour material was divided into the following
categories: (1) 12 well-differentiated endocrine tumours, including
six insulinomas, one glucagonoma, one gastrinoma (associated
with MEN 1 syndrome) and four nonfunctioning tumours; (2)
13 well-differentiated endocrine carcinomas, including two in-
sulinomas, one gastrinoma, one glucagonoma and nine nonfunc-
tioning tumours, (one was associated with MEN 1 syndrome).
Immunocytochemical analysis demonstrated NESP55 labelling
in 14 out of 25 tumours. In the group of benign tumours (well-
differentiated endocrine tumours) positive NESP55 labelling
was observed in eight out of 12 tumours. Extensive NESP55
labelling was observed in five out of six insulinomas and two out
of four nonfunctioning tumours. Focal NESP55 labelling was
observed in one out of one gastrinoma. All tumours (12 out of 12)
were strongly positive for CgA. In the group of malignant tumours
(well-differentiated endocrine carcinomas) positive NESP55 label-
ling was observed in six out of 13 carcinomas. Extensive NESP55
labelling was observed in one out of two insulinomas, while focal
NESP55 labelling was observed in one out of two insulinomas and
four out of nine nonfunctioning carcinomas. All carcinomas
(12 out of 12) were strongly positive for CgA. Neuroendocrine
secretory protein 55 labelling in benign and malignant tumours
was cytoplasmic with a strong perinuclear accumulation. In a small
population of tumour cells, the cytoplasmic NESP55 labelling was
granular, and similar to that of chromogranin A (Figures 3 and 4).
All labelling was abolished after adsorption of NESP55 antiserum
with 1mM synthetic human NESP55 peptide. A summary of clinical
and immunocytochemical results on endocrine pancreatic tumours
is given in Tables 2 and 3.
Neuroblastomas A total of 14 malignant adrenal neuroblastomas
were examined. Clinical staging of tumours was according to the
International Neuroblastoma Staging System (INSS) (Brodeur et al,
1993). Neuroendocrine secretory protein 55 labelling was detected
in seven out of 14 neuroblastomas. The labelling of tumours was
sparse to moderate (o75% of tumour cells; 1þ,2 þ). Labelling
was granular and confined to the cytoplasm of tumour cells. All
labelling was abolished after adsorption of NESP55 antiserum with
1mM synthetic human NESP55 peptide. Chromogranin A labelling
was detected in 14 out of 14 neuroblastomas. Labelling of tumour
cells was strong (475% of tumour cells; 3þ) in the majority of
tumours (13 out of 14). The labelling pattern of NESP55, CgA and
TH was compared in consecutive sections from some tumours.
Tyrosine hydroxylase labelling was extensive and present in all
tumour cells, while CgA and NESP55 labelling was more limited
and present in a subpopulation of tumour cells (Figure 3). A
summary of clinical and immunocytochemical results on neuro-
blastomas is given in Tables 2 and 4.
Pheochromocytomas A total of 19 tumours were examined and
classified according to WHO 2000: pheochromocytomas (adrenal
paragangliomas), of which 14 were benign and five malignant with
metastatic spread (Table 5). Hormonal symptoms were present in
16 out of 19 patients. Immunocytochemical results demonstrated
NESP55-labelling in all 19 pheochromocytomas, both benign and
malignant tumours. The staining was localised to the cytoplasm of
tumour cells, with a perinuclear accumulation (Figure 3). All
labelling was abolished after adsorption of NESP55 antiserum
with 1mM synthetic human NESP55 peptide. All tumours (19 out
of 19) were strongly positive for CgA, with a granular cytoplasmic
staining. A summary of clinical and immunocytochemical results
on pheochromocytomas is given in Tables 2 and 5.
Table 2 Immunocytochemical demonstration of NESP55 and CgA in 118 endocrine and nonendocrine
tumours
Tumour type Case no. NESP55 CgA
Ileal endocrine tumours (1–15) 0/15 (15, 0, 0, 0) 15/15 (0, 0, 0, 15)
Pancreatic endocrine tumours (16–40) 14/25 (11, 6, 3, 5) 25/25 (0, 0, 2, 23)
Neuroblastomas (41–54) 7/14 (7 ,6 ,1 ,0 ) 14/14 (0, 0, 1, 13)
Pheochromocytomas (55–73) 19/19 (0, 1, 2, 16) 19/19 (0, 0, 0, 19)
Adrenocortical adenomas (74–88) 0/15 (15, 0, 0, 0 ) 0/15 (15, 0, 0, 0)
Gastric carcinomas (89–94) 1/6 (5, 1, 0, 0 ) 0/6 (6, 0, 0, 0)
Colorectal carcinomas (95–103) 0/9 (9 ,0 ,0 ,0 ) 0/9 (9 ,0 ,0 ,0 )
Pancreatic carcinomas (104–118) 1/15 (14, 1, 0, 0) 0/15 (15, 0, 0, 0)
The results are given as the number of positive tumours/total number of tumours (in bold). Tumours were divided into four
categories, and the number of tumours in each category is given in parentheses (0, 1+, 2+, 3+). The categories were as
follows: 0 o1% positive cells, 1+¼1–24% positive cells, 2+¼25–75% positive cells, 3+¼475% positive cells.
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were examined, and classified as benign adrenocortical adenomas
according to Weiss (1984): four nonfunctioning tumours, four
Conn tumours and seven tumours with Cushing syndrome.
Immunocytochemical analysis revealed no NESP55 or CgA
labelling in any of the tumours (Table 2).
Nonendocrine tumours of the gastrointestinal tract The following
nonendocrine tumours of the gastrointestinal tract were examined:
six gastric adenocarcinomas, nine colorectal adenocarcinomas and
15 pancreatic carcinomas. Immunocytochemical results demon-
strated no NESP55 labelling in the majority of the tumours (28 out
of 30). One gastric adenocarcinoma, and one pancreatic adeno-
carcinoma contained scattered NESP55-labelled cells. CgA was
absent in all of the tumours (30 out of 30) (Table 2).
Characterisation of NESP55 protein in endocrine tumours
by Western blot
Western blot analysis demonstrated NESP55 expression in five out
of nine adrenal pheochromocytomas (all benign tumours), and in
four out of nine pancreatic endocrine tumours. All NESP55-
expressing endocrine pancreatic tumours were insulin-producing
(1 malignant and three benign insulinomas), while all NESP55-
negative tumours were nonfunctioning malignant tumours. The
NESP55 immunoreactive protein in pheochromocytomas and
endocrine pancreatic tumours migrated as a major band of 45–
55kDa. In some tumours, an additional minor band of approxi-
mately 40kDa was detected. Adsorption of NESP55 antiserum with
1mM of synthetic human NESP55 peptide (GPIPIRRH) totally
abolished both NESP55 bands. None of the ileal carcinoids (n¼9)
EPT - CgA EPT - NESP55 EPT - Insulin
PC - CgA PC - NESP55 PC - TH
NB - CgA NB - NESP55 NB - TH
Figure 3 Immunocytochemical demonstration of CgA and NESP55 in a pancreatic endocrine tumour (EPT, malignant insulinoma), an adrenal
pheochromocytoma (PC) and a neuroblastoma (NB). Consecutive sections were stained with an indirect immunoperoxidase technique (EnVisionþt). The
majority of tumour cells are positive for CgA and NESP55. TH¼tyrosine hydroxylase.
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pressed NESP55 protein (Figures 5 and 6).
Analysis of NESP55 transcripts in endocrine tumours by
Northern blot
Northern blot analysis of NESP55 mRNA demonstrated a
transcript of approximately 3kb in adrenal pheochromocytomas
(n¼5). No NESP55 transcripts were detected in ileal endocrine
tumours (n¼3) (Figure 7).
DISCUSSION
Neuroendocrine tumours are characterised by their content of
secretory granules and vesicles. Components from these organelles
are frequently used to identify and classify neuroendocrine
tumours. Vesicle membrane proteins, such as synaptophysin and
SV2, are used as general markers since they are present in virtually
all neuroendocrine tumours (Jakobsen et al, 2002). Other vesicle
membrane proteins, for example, VMAT 1 and 2, are expressed in
a limited number of neuroendocrine tumours, but can be used to
identify subgroups of tumours, and may indicate potential
treatment strategies (Jakobsen et al, 2001). Granule proteins
located to dense core, for example, chromogranins, are also used
as general markers of neuroendocrine differentiation since almost
all neuroendocrine tumours express CgA. In the present study, we
have evaluated the expression of NESP55 in human endocrine and
nonendocrine tumours and compared it with CgA expression. We
found by immunocytochemistry that pancreatic endocrine tu-
mours, pheochromocytomas and neuroblastomas expressed the
NESP55 protein regardless of malignant potential and tumour
CgA NESP55
Figure 4 Immunocytochemical demonstration of CgA and NESP55 in a
pancreatic endocrine tumour (EPT, malignant insulinoma). Chromogranin A
antibodies gave a granular staining of all cytoplasm in tumour cells. NESP55
antibodies gave a cytoplasmic staining of tumour cells that was partly
granular and concentrated to the perinuclear region. Indirect immunoper-
oxidase staining (EnVisionþt).
Table 3 Clinical and immunocytochemical findings in 25 pancreatic endocrine tumours
Case
no. Age Sex
Hormonal
Syndrome
Metastases Clinical outcome ICC findings
Lgl Liver Years NED AWD DWD DOD NESP55 CgA
Well-differentiated endocrine tumour
Insulinoma 16 62 M Yes — — 1 X 0 0 0 2+ 3+
17 80 F Yes — — 8 X 0 0 0 3+ 3+
18 17 F Yes — — 3 X 0 0 0 3+ 3+
19 32 F Yes — — 1 X 0 0 0 — 3+
20 83 F Yes — — 1 X 0 0 0 3+ 3+
21
a 68 F Yes — — 7 X 0 0 0 3+ 3+
Glucagonoma 22 50 F Yes — — 7 X 0 0 0 — 3+
Gastrinoma 23
a 55 M Yes — — 3 X 0 0 0 1+ 3+
Nonfunctioning 24 63 F No — — 4 X 0 0 0 — 3+
25 63 M No — — 1 X 0 0 0 2+ 3+
26 25 M No — — 11 X 0 0 0 — 3+
27 76 F No — — 4 X 0 0 0 2+ 3+
Well-differentiated endocrine carcinoma
Insulinoma 28 62 M Yes + — o10 0 X
b 03 + 3 +
29 69 M Yes — + o10 0 X
c 01 + 3 +
Glucagonoma 30 49 M Yes + — 6 X 0 0 0 — 3+
Gastrinoma 31 30 F Yes — + 7 0 0 0 X — 3+
Nonfunctioning 32 48 M No —
d — 2 0 X 0 0 1+ 3+
33
a 55 M No + — 2 0 X 0 0 — 2+
34 53 M No + + 3 X 0 0 0 1+ 3+
35 40 M No — + 4 X
e 00 0 1 + 3 +
36 49 M No + — 4 0 X 0 0 1+ 3+
37 47 M No + — 1 0 0 0 X — 2+
38
f 55 F No + — 5 X 0 0 0 — 3+
39 58 F No + + 5 0 X 0 0 — 3+
40 45 F No + + 7 X
g 00 0— 3 +
Age¼age at diagnosis and primary surgery. F¼female, M¼male. Metastases: Lgl¼lymph node metastases, liver¼liver metastases. Clinical outcome: Years¼observation time.
X indicates outcome at follow up, which was categorized as NED¼alive, no evidence of disease. AWD¼alive with disease. DWD¼dead with disease. DOD¼dead of
disease. ICC findings: The categories were as follows: 0¼o1% positive cells, 1+¼1–24% positive cells, 2+¼25–75% positive cells, 3+¼475% positive cells.
aMEN 1
syndrome.
bDied postoperatively because of surgical complications.
cDied from metastatic rectal carcinoma.
dTumour invading large vessels.
eTreated with orthotopic liver
transplantation (OLT) following diagnosis, treated for local recurrence 3 years post-OLT, and treated for adrenal metastases 4 years post-OLT.
fVon Hippel–Lindau syndrome.
gTreated with orthotopic liver transplantation (OLT), 5 years after primary surgery because of liver metastases.
NESP55 in endocrine tumours
A-M Jakobsen et al
1751
British Journal of Cancer (2003) 88(11), 1746–1754 & 2003 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
ystage. Western and Northern blot analysis confirmed expression of
NESP55 in pancreatic endocrine tumours and pheochromocyto-
mas. Northern blot analysis of NESP55 in tumour tissues
demonstrated a single mRNA transcript of 3kb, a pattern that
was different from that observed in normal rat tissues, where five
distinct transcripts have been identified (Weiss et al, 2000).
NESP55 could not be detected in ileal carcinoids. Thus, the
expression of NESP55 was different from that of CgA, which was
expressed in all neuroendocrine tumours investigated, regardless
of hormone production, cellular composition or malignant
potential. These results demonstrate that NESP55 is expressed by
a subset of neuroendocrine tumours, and that NESP55 cannot be
regarded as a general neuroendocrine tumour marker. In normal
tissues, NESP55 was present in chromaffin cells of the adrenal
medulla and in pancreatic islet cells. Tumours originating from
these organs also expressed NESP55, reflecting their origin and
cellular composition.
The function of NESP55 in neuroendocrine tumours is
unknown. The role of the chromogranins in normal cells is not
yet fully understood. However, it has recently been proposed that
CgA regulates secretory granule biogenesis in endocrine and
neuroendocrine cells (Kim et al, 2001). All known chromogranins
including NESP55 are proteolytically processed, to give rise to
smaller peptide fragments, some of which possess biological
activity. We suggest that NESP55 in neuroendocrine tumours
may serve a function in secretory granule formation and that
Table 4 Clinical and immunocytochemical findings in 14 neuroblastomas
Clinical outcome ICC findings
Case no. Age Sex Stage N-myc NSE HVA VMA DA Years NED AWD DWD DOD NESP55 CgA
41 o1M 1 N DN D5 6 3 5 N D 1 2 X 0 0 0 — 3 +
42 o1 M 2B — 14 95 112 430 5 X 0 0 0 — 3+
43 o1F 2 B410 13 30 19 1358 5 X 0 0 0 +1 3+
44 3M 3 410 210 180 51 40079 2 0 0 0 X +1 3+
45 3 F 3 ND ND 150 47 41608 1 0 0 0 X +1 3+
46 2 F 3 ND ND 36 6.9 ND 9 X 0 0 0 +1 3+
47 1 F 3 ND ND 440 343 9277 8 X 0 0 0 +1 3+
48 1 F 3 ND 68 130 300 ND 14 X 0 0 0 +2 3+
49 4M 4 470 ND 3.7 13 ND 1 0 0 0 X — 2+
50 2 F 4 — 200 87 6.2 ND 1 0 0 0 X — 3+
51 1M 4 N DN D8 5 1 4 N D 2 0 0 0 X — 3 +
52 o1F 4 410 12 17 15 1665 12 X 0 0 0 — 3+
53 5 M 4 — 270 30 17 2454 1 0 0 0 X +1 3+
54 3 M 4 ND ND 318 498 ND 3 0 0 0 X — 3+
Age¼age at diagnosis . F¼female, M¼male. Stage according to the International Neuroblastoma Staging System (INSS). N-myc¼amplification of N-myc gene. NSE¼neuron-
specific enolase. HVA¼homovanillic acid. VMA¼vanillylmandelic acid. DA¼dopamine. Years¼observation time. X indicates outcome at follow up, which was categorized as
NED¼alive, no evidence of disease. AWD¼alive with disease. DWD¼Dead with disease. DOD¼dead of disease. ICC findings: The categories were as follows: 0¼o1%
positive cells, 1+¼1–24% positive cells, 2+¼25–75% positive cells, 3+¼475% positive cells. ND¼not determined.
Table 5 Clinical and immunocytochemical findings in 19 pheochromocytomas
Clinical outcome ICC findings
Case no. Age Sex Malignant/benign
Hormonal
syndrome Years NED AWD DWD DOD NESP55 CgA
55 47 F Benign Yes 8 X 0 0 0 3+ 3+
56 53 M Benign Yes 7 X 0 0 0 3+ 3+
57 27 F Benign Yes 3 X 0 0 0 3+ 3+
58 48 M Benign Yes 8 X 0 0 0 3+ 3+
59 52 M Benign Yes 4 X 0 0 0 3+ 3+
60 73 M Benign Yes 1 X 0 0 0 3+ 3+
61 52 M Benign Yes 1 X 0 0 0 3+ 3+
62
a 38 F Benign No 2 X 0 0 0 3+ 3+
63 47 F Benign Yes 3 X 0 0 0 2+ 3+
64 20 F Benign Yes 2 X 0 0 0 3+ 3+
65
b 18 M Benign Yes 1 X 0 0 0 3+ 3+
66
c 20 F Benign Yes 7 X 0 0 0 2+ 3+
67 61 F Benign Yes 4 X 0 0 0 1+ 3+
68 56 M Benign Yes 2 X 0 0 0 3+ 3+
69 76 F Malignant Yes 8 0 0 X 0 3+ 3+
70 36 F Malignant No 23 0 0 0 X 3+ 3+
71 55 M Malignant No 14 X 0 0 0 3+ 3+
72 58 M Malignant Yes 1 0 0 X 0 3+ 3+
73 61 M Malignant Yes 9 0 0 X 0 3+ 3+
Age¼age at diagnosis and primary surgery. F¼female, M¼male. Clinical outcome: Years¼observation time. X indicates outcome at follow up, which was categorized as
NED¼alive, no evidence of disease. AWD¼alive with disease. DWD¼dead with disease. DOD¼dead of disease. ICC findings: The categories were as follows: 0¼o1%
positive cells, 1+¼1–24% positive cells, 2+¼25–75% positive cells, 3+¼475% positive cells.
aTurner’s syndrome,
bFamilial pheochromocytoma, genetic defect unknown.
cMEN 2B syndrome.
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may influence tumour cell growth/secretion.
In conclusion, we have demonstrated that NESP55 is expressed
in neuroendocrine tumours of the pancreas and adrenals. The
distribution of NESP55 differs from that of CgA in neuroendocrine
tumours. The expression of NESP55 reflects the origin and cellular
composition of neuroendocrine tumours and may therefore
become a valuable marker in diagnostic histopathology.
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